29:04

Resect and Protect Against Melanoma Recurrence

01:23:59

A New Script for SCD Care

44:10

Renewed Optimism for Personalized Care in Advanced Pancreatic & Extra Pancreatic NETs

39:31

Accelerating Personalized Care in CRC: Predictive Biomarkers and Immunotherapy Platforms

01:24:52

Guiding Multifactorial Clinical Decisions in HR+, HER2- Breast Cancer

01:00:07

The Role of Epithelial Cytokines in CRSwNP: New Approaches With Targeted Biologic Therapy

02:06

The Role of Epithelial Cytokines in CRSwNP

55:47

Optimizing PARP Inhibitor Therapies in Veterans With Prostate Cancer

59:39

Integrating Personalized, Multidisciplinary Care in Dedifferentiated Liposarcoma

45:07

Integrating Immunotherapy in Resectable NSCLC

44:25

Reinforcing Precision Tactics in Genomically Altered Resectable NSCLC

01:24:52

Guiding Multifactorial Clinical Decisions in HR+, HER2- Breast Cancer

36:54

Immunotherapy in Advaced BTC Standardizing Team Based Strategies With Immune Checkpoint Inhibitors

01:14

Tarlatamab Mechanism of Action

30:52

Taking a BiTE Out of SCLC

58:41

Exceeding Expectations in CLL: Targeted Standards, Sequential Options, and Emerging Therapeutics

55:59

Leveraging Immunotherapy and EGFR Targeted Treatment in Unresectable Stage III NSCLC

54:19

Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates

01:14:57

Embracing Progress, Transforming Treatment, Empowering Patients

01:09:38

Resetting Standards in MDS

01:03:31

Elevating Care in Resectable Stage I-III NSCLC

01:06:30

Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine

59:03

Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC

01:03:04

Opportunity Knocks in AML

21:36

Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC?

59:12

Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast Cancer

01:05:37

Focusing Decision-Making & Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC

01:16:56

Navigating the Integration of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer

35:53

Advancing Immunotherapy in Cervical Cancer Care

37:22

Mapping a New Treatment Journey in NF1

43:08

Renovating Frontline Care for Metastatic Melanoma

01:27:09

Optimal SCLC Care With Established and Innovative Therapies

01:29:10

Multidirectional HCC Tactics: Expert Guidance on Emerging Trends With Systemic Therapy Options

36:41

Clotting the Gaps in VWD Care

54:53

Transforming MCL Management Guidance on Selecting and Using BTKi Platforms as First Line Therapy

01:12:47

Innovation in CLL The Practicalities and Potential of Finite Therapy With BTKi Platforms

01:32:29

Candid Conversations on Modern Urothelial Cancer Management

01:57:53

Unleashing the Innovation Era in AML

49:39

Advances in Endometrial Carcinoma Treatment: The Power of Immunotherapy and Other Emerging Regimens

01:22:09

Illuminating the Path With Immunotherapy for Metastatic, Locally Advanced, and Early Stage NSCLC

01:53:26

Three Rs for Modern Myeloma Care

35:57

On Target: Using Trop-2-Directed Therapeutics for Urothelial Carcinoma

48:32

Expanding Frontline Frontiers in Multiple Myeloma Care

01:25:15

Decoding Biomarker Testing and Targeted Therapy in NSCLC

59:36

CONTROL Myelofibrosis

01:31:33

Maximizing the Role of ADCs in Urothelial Carcinoma

01:32:31

Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer

01:22:29

Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

01:35:13

Catalysts for Change in Gastric & GEJ Cancer

55:49

HR+, HER2 , High Risk EBC A Practical Roadmap for CDK4 6 Inhibition in the Adjuvant Setting

02:19

Overcoming BTK Resistance With Non-Covalent BTKi

57:49

The Collaborative Benchmark for HCC: Critical Discussions Between IR–Oncology Professionals

33:20

Five Steps for Integrating BCMA Bispecific Innovations: Clinical Data to Clinical Practice in RRMM

48:02

Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC

01:04:14

Pharmacy Takes on Navigating the Therapeutic Landscape for Endometrial & Cervical Cancers

01:02:43

Modern Team-Based Therapeutic Management for Bladder Cancer Care

41:22

Striking Back at ALL With Antibody Regimens

01:23:25

Harnessing Innovation in Bladder Cancer Care

28:34

“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets

01:24:16

Ten Steps for Highly Successful Myeloma Care